v3.26.1
Summary of Significant Accounting Policies - Segment (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
segment
Jun. 30, 2025
USD ($)
Accounting Policies [Abstract]        
Number of operating segments | segment     1  
Research And Development Expense By Major Programs [Line Items]        
Research and development $ 8,798 $ 40,517 $ 21,425 $ 91,328
Birtamimab (NEOD001)        
Research And Development Expense By Major Programs [Line Items]        
Research and development (70) 19,433 (39) 45,347
PRX012        
Research And Development Expense By Major Programs [Line Items]        
Research and development 2,261 15,093 7,614 33,168
PRX019        
Research And Development Expense By Major Programs [Line Items]        
Research and development 1,231 1,824 3,358 3,926
Other Research And Development        
Research And Development Expense By Major Programs [Line Items]        
Research and development $ 5,376 $ 4,167 $ 10,492 $ 8,887